Browsing Tag
non-muscle invasive bladder cancer
11 posts
Johnson & Johnson fortifies urologic oncology pipeline with compelling Inlexzo results
Johnson & Johnson's new data show Inlexzo delivers strong one-year disease-free survival. Find out how it could shift bladder cancer care.
Relmada gains FDA support for dual Phase 3 study paths of NDV-01 in non-muscle invasive bladder cancer
Find out how Relmada secured FDA alignment on dual Phase 3 paths for NDV-01 in NMIBC, opening two routes toward approval and a potential new bladder-sparing therapy.
Valar Labs’ AI biomarkers validated in European Urology as superior risk predictors for bladder cancer
Valar Labs’ CHAI biomarkers validated in European Urology outperform standard methods in predicting outcomes for high grade Ta bladder cancer.
Hope for bladder cancer patients? UroGen’s UGN-301 shows strong safety and clinical activity in early trial
Find out how UroGen Pharma’s UGN-301 is offering new hope for bladder cancer patients with promising Phase 1 trial results. Read the latest developments here!
Photocure’s blue light cystoscopy demonstrates 38% recurrence reduction in BRAVO study
Photocure ASA, a bladder cancer company, has unveiled new clinical evidence demonstrating the advantages of blue light cystoscopy…
Ferring bags Adstiladrin FDA approval in non-muscle invasive bladder cancer
Swiss biopharmaceutical company Ferring Pharmaceuticals has received approval for its Adstiladrin (nadofaragene firadenovec-vncg) gene therapy from the US…
Aura Biosciences begins dosing in belzupacap sarotalocan phase 1 trial in NMIBC
Aura Biosciences said that it has dosed the first patient in a phase 1 clinical trial of its…
Aura Biosciences gets FDA fast track status for belzupacap sarotalocan
Aura Biosciences has secured fast track designation for belzupacap sarotalocan (AU-011) from the US Food and Drug Administration…
Ferring, Blackstone invest $570m in nadofaragene firadenovec gene therapy
Ferring Pharmaceuticals, a Swiss specialty biopharmaceutical group, has teamed up with private investment platform Blackstone Life Sciences to…
LIPAC Oncology takes NMIBC treatment TBC-1002 into phase 2 A trial
Investigational NMIBC treatment TBC-1002 : LIPAC Oncology said that it has wrapped up a phase 1 clinical trial…